Literature DB >> 8708739

Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy.

G A Fyfe, R I Fisher, S A Rosenberg, M Sznol, D R Parkinson, A C Louie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8708739     DOI： 10.1200/JCO.1996.14.8.2410

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  44 in total

1.  An update on current management of advanced renal cell cancer, biomarkers, and future directions.

Authors:  Wanqing Iris Zhi; Jenny J Kim
Journal:  Ann Cancer Res       Date:  2014

Review 2.  Functions of γC cytokines in immune homeostasis: current and potential clinical applications.

Authors:  Willem W Overwijk; Kimberly S Schluns
Journal:  Clin Immunol       Date:  2009-05-09       Impact factor: 3.969

3.  [New therapeutic regimes in metastasic renal-cell carcinoma].

Authors:  S Bierer; L Hertle; S Nitschmann
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

Review 4.  Trial Watch-Immunostimulation with cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

5.  [Immunotherapy for advanced renal cell cancer].

Authors:  S Schmidt; F Kunath; N Kroeger
Journal:  Urologe A       Date:  2015-05       Impact factor: 0.639

6.  Systemic therapy for metastatic renal cell carcinoma: a review and update.

Authors:  Joshua E Logan; Edward N Rampersaud; Geoffrey A Sonn; Karim Chamie; Arie S Belldegrun; Allan J Pantuck; Dennis J Slamon; Fairooz F Kabbinavar
Journal:  Rev Urol       Date:  2012

7.  Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.

Authors:  Anne Flörcken; Joachim Kopp; Antje van Lessen; Kamran Movassaghi; Anna Takvorian; Korinna Jöhrens; Markus Möbs; Constanze Schönemann; Birgit Sawitzki; Karl Egerer; Bernd Dörken; Antonio Pezzutto; Jörg Westermann
Journal:  Hum Vaccin Immunother       Date:  2013-03-04       Impact factor: 3.452

8.  SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer.

Authors:  Guoqiang Li; Weimin Ci; Subhradip Karmakar; Ke Chen; Ruby Dhar; Zhixiang Fan; Zhongqiang Guo; Jing Zhang; Yuwen Ke; Lu Wang; Min Zhuang; Shengdi Hu; Xuesong Li; Liqun Zhou; Xianghong Li; Matthew F Calabrese; Edmond R Watson; Sandip M Prasad; Carrie Rinker-Schaeffer; Scott E Eggener; Thomas Stricker; Yong Tian; Brenda A Schulman; Jiang Liu; Kevin P White
Journal:  Cancer Cell       Date:  2014-03-20       Impact factor: 31.743

Review 9.  Recent developments in the treatment of renal cell carcinoma.

Authors:  Janice P Dutcher
Journal:  Ther Adv Urol       Date:  2013-12

10.  Sunitinib for advanced renal cell cancer.

Authors:  Chris Coppin
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.